Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.53M | 8.59M | 4.40M | 3.83M | 3.78M | 3.67M |
Gross Profit | 10.53M | 8.59M | 4.40M | 3.83M | 3.78M | 3.67M |
EBITDA | -1.14M | -382.00K | -1.19M | -1.34M | 552.35K | -839.00K |
Net Income | -309.14K | 169.30K | -780.00K | -1.14M | 585.86K | -715.00K |
Balance Sheet | ||||||
Total Assets | 17.94M | 20.28M | 10.98M | 11.69M | 12.44M | 10.50M |
Cash, Cash Equivalents and Short-Term Investments | 3.51M | 6.85M | 6.36M | 6.78M | 8.86M | 6.97M |
Total Debt | 3.60M | 3.70M | 272.94K | 268.22K | 60.10K | 116.10K |
Total Liabilities | 7.90M | 9.35M | 1.05M | 995.58K | 611.74K | 591.04K |
Stockholders Equity | 10.04M | 10.93M | 9.94M | 10.69M | 11.83M | 9.91M |
Cash Flow | ||||||
Free Cash Flow | 2.41M | 1.01M | -624.93K | -1.42M | 772.72K | 1.06M |
Operating Cash Flow | 2.53M | 1.39M | -157.03K | -712.67K | 1.17M | 1.31M |
Investing Cash Flow | -7.77M | -3.94M | -467.90K | -704.00K | -395.79K | -250.63K |
Financing Cash Flow | 2.78M | 3.01M | -81.97K | -107.11K | 1.20M | 2.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | AU$19.76M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
55 Neutral | AU$66.31M | ― | -457.46% | ― | 21.93% | 10.34% | |
54 Neutral | AU$107.10M | ― | ― | ― | ― | ||
52 Neutral | kr5.55B | 11.43 | -72.81% | 7.82% | 28.10% | 22.23% | |
46 Neutral | AU$15.29M | ― | -17.24% | ― | 34.47% | 41.83% | |
44 Neutral | AU$16.51M | ― | -74.80% | ― | -9.16% | 89.23% | |
39 Underperform | AU$6.90M | ― | ― | 18.53% | 33.17% |
Resonance Health Ltd is expanding its TrialsWest business with the opening of a third clinical trial site in Mandurah, Western Australia, expected in August 2025. This expansion is part of the company’s strategy to increase participant capacity and enhance its clinical trial operations, particularly for major pharmaceutical trials. The new site in Mandurah, a rapidly growing city, aligns with the company’s goal to establish trial sites in accessible, densely populated areas with low setup costs, supporting its long-term growth and market positioning.
Resonance Health Ltd has announced a change in the director’s interest, with Simon Panton acquiring an additional 500,000 ordinary fully paid shares through an on-market trade. This acquisition, valued at $17,500, increases Panton’s total shareholding to 74,800,000 shares, reflecting a strategic move that could influence the company’s governance and shareholder dynamics.
Resonance Health Ltd has launched ‘InvestorHub’, a new platform aimed at enhancing engagement with investors and market participants. This initiative is part of the company’s strategy to support its growth across three business areas: Clinical Trial Management, SaMD Image Analysis Services, and Clinical Trial Site Services. The InvestorHub will provide a centralized location for shareholders to access company announcements and updates, fostering better communication and interaction with the company’s leadership. This move is expected to support Resonance Health’s ongoing expansion and innovation efforts, as it continues to scale its operations and strengthen its market position.
Resonance Health Ltd reported record cash receipts of $14.9M over the last 12 months, with a positive cash flow from operations. The company completed a cost efficiency program, resulting in significant annual savings, and is progressing with major clinical trials and contract extensions in its SaMD business. The TrialsWest division is set for strong growth with new contracts and expanded capacity. The company is enhancing automation and efficiency to serve more customers at a lower cost, expecting annual savings of approximately $1.1M.